New R&D tax incentives for SMEs, funding for the medicines regulator and ‘hidden benefits’ delight the UK bioindustry.
The medtech company and its fellow tech giant plaintiffs can now challenge the controversial rule.
“Customer suit exception” is rejected by district judge leaving the suit involving Chr. Hansen and Glycosyn ongoing.
The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.
New R&D tax incentive announced for SMEs in UK Budget | Funding for medicines regulator aims to open up drug approvals | ‘Hidden benefits’ in Budget for industry | Reaction from Bioindustry Association, Potter Clarkson, Mischon de Reya, Marks & Clerk, Taylor Wessing.